Real-world studies confirm that pairing LONSURF with bevacizumab increases efficacy in patients with metastatic colorectal cancer </b ...

Three-fourths of patients with unresectable gastroesophageal cancer converted to resectable and had clear margins after ...

Results of 3 trials revealed that omitting transplant did not impact progression or survival outcomes for pediatric, ...

Adding evorpacept to treatment with trastuzumab, ramucirumab, and paclitaxel may improve outcomes in HER2-positive gastric/GEJ cancer.

Rigel Pharmaceuticals, Inc.  today announced the first patient has been enrolled in a Phase 1 study evaluating the safety and tolerability of escalating doses of fostamatinib, the company's oral ...

Ten days of subcutaneous Dacogen resulted in responses among a third of patients with myelofibrosis. Among patients with ...

The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for ...

Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces an oral ...

CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma ...

The Food and Drug Administration has granted traditional approval to Calquence with bendamustine and Rituxan for some ...

Myelosuppression, or bone marrow suppression, is defined as a decrease in the ability of the bone marrow to produce blood cells. This may result in a lack of red blood cells (anemia), white blood ...